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Histopathologic, immunophenotypic, and proteomics
characteristics of low-grade phyllodes tumor and
fibroadenoma: more similarities than differences
Lingxin Zhang 1,3,5✉, Chen Yang 1,3,5, John D. Pfeifer1, Richard M. Caprioli2, Audra M. Judd2, Nathan H. Patterson 2,
Michelle L. Reyzer2, Jeremy L. Norris2 and Horacio M. Maluf 1,4✉
Distinguishing low-grade phyllodes tumor from fibroadenoma is practically challenging due to their overlapping histologic
features. However, the final interpretation is essential to surgeons, who base their management on the final pathology report.
Patients who receive a diagnosis of fibroadenoma might not undergo any additional intervention while lumpectomy with wide
margins is the standard of care for phyllodes tumor, which can have significant cosmetic consequences. We studied the clinical,
immunophenotypic, and proteomics profiles of 31 histologically confirmed low-grade phyllodes tumor and 30 fibroadenomas.
Matrix-assisted laser desorption ionization (MALDI) imaging mass spectrometry (IMS) and immunohistochemistry for Ki-67, p53,
β-catenin, and E-cadherin were performed on all cases. After the mass spectra for all 31 cases of low-grade phyllodes tumor and
30 cases of fibroadenoma were collected, an average peak value for all cases was generated. There was no significant difference in
the overall mass spectra pattern in any of the peaks identified. There was also overlap in the percentage of cells staining positive for
Ki-67, p53, β-catenin, and E-cadherin. The two groups of patients showed no statistically significant difference in age, tumor size, or
disease-free survival. Neither group developed malignant transformation, distant metastases, or disease-related mortality. We have
demonstrated low-grade phyllodes tumor and fibroadenoma to show significant overlapping clinical and proteomics features.
npj Breast Cancer            (2020) 6:27 ; https://doi.org/10.1038/s41523-020-0169-8
INTRODUCTION
Fibroepithelial lesions of the breast are a heterogeneous group of
biphasic tumors that include the common benign fibroadenomas
and the relatively rare phyllodes tumors (2.5% of all fibroepithelial
lesions of the breast). Current treatment guidelines rely on
histologic diagnosis on either core or excisional biopsy and
recommend wide excision without axillary staging to treat
phyllodes tumors regardless of grade1. However, phyllodes tumor
represents a heterogenous group of neoplasms that display highly
variable prognosis2.
Many grading systems for phyllodes tumor have been
proposed, all based on the assessment of tumor borders, stromal
cellularity and atypia, mitotic activity, and stromal overgrowth. The
World Health Organization (WHO)2 recommended a three-tier
grading system (benign, borderline, malignant), while the Armed
Forces Institute of Pathology (AFIP) proposed a two-tier system
(low-grade, high-grade)3 with slight variation in their cutoff
criteria. AFIP defines low-grade phyllodes tumors as fibroepithelial
neoplasms with well-defined borders, uniform leaf-like processes,
rare to moderate mitoses (<3 mitoses per 10 high-power fields),
mildly increased cellularity often with subepithelial accentuation,
no to mild cytological atypia and no sarcomatous stromal
overgrowth. The low-grade category proposed by the AFIP would
include the majority of benign phyllodes tumors and a subset of
borderline phyllodes tumors.
Despite the above well-established diagnostic criteria, distin-
guishing low-grade phyllodes tumor from fibroadenoma is
challenging due to their overlapping histologic features (Fig. 1).
Recent study by Lawton et al.4 showed that there is significant
inter-observer variability, even among pathologists who specialize
in breast pathology, when making diagnosis of either benign
phyllodes tumor or fibroadenoma in a research setting. The issue
is more significant in small core biopsies, which determines
whether the fibroepithelial lesion should be observed (fibroade-
noma) or excised with a wide margin (phyllodes tumor)5. The
justification for the latter is on the basis of reported local
recurrences of phyllodes tumors6. This diagnostic dilemma on
core needle biopsies has been highlighted during recent attempts
of incorporating digital pathology into routine practice7. To date,
there are no clinically validated immunohistochemical assays to
facilitate the differential diagnosis.
The application of matrix-assisted laser desorption ionization
(MALDI) imaging mass spectrometry (IMS) on formalin-fixed,
paraffin-embedded tissue allows for the label-free, multiplex
analysis of thousands of analytes across the tissue surface and
elucidate both the localization and relative abundance of
endogenous metabolites, lipids, peptides, and proteins8. Since
the development of histology-directed MALDI-IMS technique8,
there have been several feasibility studies exploring its utility in
the facilitation of challenging histologic diagnoses9–11. One
main advantage of histology-directed MALDI-IMS is the ability
to interrogate the proteomics profile of individual tumor
components. This approach has definite appeal in our case, as
both phyllodes tumors and fibroadenomas are biphasic tumors,
it would be of significant interest to compare the epithelial
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and stromal components between the two biphasic lesions
independently.
The aim of this study was to perform a comprehensive
evaluation of the clinical, histopathologic, immunophenotypic,
and proteomics characteristics of low-grade phyllodes tumor and




A total of 31 patients with low-grade phyllodes tumor (including
22 cases of benign and 9 cases of borderline phyllodes tumors
with archived materials available for analysis in our institution,
Supplementary Table 1) and 30 patients with fibroadenoma were
included in our analysis. All patients were female. There was a
slight trend that show low-grade phyllodes tumor to be more
commonly seen in older patients with a median age of 39.0 years
and a mean age of 35.5 years (range 14 to 63 years), compared to
patients with fibroadenoma who had a median age of 24.5 years
and a mean age of 27.0 years (range 15 to 49 years). However,
difference in age was not statistically significant (Fig. 2a). There
was also no statistically significant difference in the size of low-
grade phyllodes tumor and fibroadenomas (Fig. 2b). Low-grade
phyllodes tumors had a median size of 2.8 cm and a mean size of
3.0 cm (range 0.8 to 7.0 cm) at the time of resection, only
marginally larger than the median size of 2.5 cm and mean size of
2.7 cm (range 1.2 to 5.1 cm) of fibroadenomas at the time of
surgery.
On clinical follow-up, 24 of 31 (77.4%) cases with the diagnosis
of low-grade phyllodes tumor had re-excision of the tumor bed
performed, whereas none of the cases with the diagnosis of
fibroadenoma undergone additional intervention. This is consis-
tent with the current standard of care. The median follow-up time
for low-grade tumor was 47.0 months (mean 44.6 months, range 0
to 131 months), compared to the 61.5 months median follow-up
time for fibroadenoma (mean 59.2 months, range 0 to
109 months). Two of 31 patients (6.5%) with low-grade phyllodes
tumor subsequently developed recurrence of disease, and upon a
second excision procedure, there were no further recurrences.
Although none of the 30 patients with fibroadenoma developed
“recurrences,” it is important to note that one patient presented
with new ipsilateral breast mass, one patient with contralateral
breast mass, and one patient with bilateral breast masses. None of
which were biopsied under the clinical impression that these were
fibroadenomas. The disease-free Kaplan–Meier curve is presented
to show no significant difference in Fig. 3a. There were no
malignant transformation, distant metastasis, or mortality related
to disease in the low-grade phyllodes tumor or fibroadenoma
group. The Kaplan–Meier curve for overall survival is shown in
Fig. 3b.
Immunohistochemistry
There is significant overlap in the percentage of cells staining
positive for Ki-67, p53, β-catenin, and E-cadherin between low-
grade phyllodes tumor and fibroadenoma (Figs. 4 and 5). Ki-67
had a median positivity of 6.0% (mean 7.7%, range 2 to 30%) in
low-grade phyllodes tumor, higher than the 2.0% (mean 2.5%,
range 1 to 10%) seen in fibroadenoma. p53 had a median
positivity of 3.0% (mean 10.0%, range 1 to 60%) in low-grade
phyllodes tumor, which was also higher than the 1.0% (mean
2.7%, range 1 to 20%) seen in fibroadenoma. β-catenin had a
Fig. 1 Comparison of histologic features of fibroadenoma and low-grade phyllodes tumor. Histologic features of fibroadenoma (a, 20×)
and low-grade phyllodes tumor (b, 20×). Note that there is significant histologic overlap between the two entities.
Fig. 2 Comparison of patient age and tumor size distribution of low-grade phyllodes tumor (LGP) and fibroadenoma (FA). Dot plot of
individual data points, with a horizontal line at the arithmetic mean and error bars showing plus and minus one standard deviation, shows
significant overlap in patient age (a) and tumor size (b) between LGP and FA. Wilcoxon-Mann–Whitney tests show no statistical difference in
distribution of patient age or tumor size between the two groups.
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median positivity of 60.0% (mean 48.8%, range 2 to 90%) in low-
grade phyllodes tumor, again slightly overexpressed, compared to
the 40.0% (mean 38.2%, range 0 to 80%) seen in fibroadenoma.
However, this was not statistically significant. E-cadherin demon-
strated no staining in any stromal cells while exhibiting 100%
strong positivity in the epithelial component in both low-grade
phyllodes tumors and fibroadenomas.
In contrast, high-grade phyllodes tumor showed minimal
overlap and statistically significantly different staining pattern
for Ki-67, p53, and β-catenin (Figs. 4 and 5) compared with either
low-grade phyllodes tumor group or fibroadenoma group. Ki-67
highlighted a median proliferation index of 50.0% (mean 45.0%,
range 20 to 70%), p53 showed a median staining of 20.0% (mean
30.5%, range 2 to 100%), and β-catenin had a median staining of
0% (mean 9.5%, range 0 to 40%). E-cadherin showed the same
pattern as low-grade phyllodes and fibroadenomas and was
completely negative in the stromal tumor cells.
The results of the immunohistochemistry study are summarized
in Table 1.
MALDI imaging mass-spectrometry
A total of 21 cases of low-grade phyllodes tumor and another 20
cases of fibroadenoma were randomly selected as the study set to
generate an algorithm to distinguish low-grade phyllodes tumor
and fibroadenoma. This algorithm was then tested on a validation
set of remaining ten cases of low-grade phyllodes tumor and
fibroadenoma. The initial mass spectra generated from the study
set showed only few peaks with >1-fold difference and fewer
peaks that showed statistical significance. There is greater
proteomic variability between the stromal compared to the
epithelial component in these two tumor types (Fig. 6). However,
when the algorithm is applied to the validation set, only 10 (50%)
cases were correctly identified by the algorithm (8 of 10 low-grade
phyllodes tumors and 2 of 10 fibroadenomas). Only 7 (35%) cases
were consistently identified as either phyllodes tumor or
fibroadenoma across all annotated areas, while the remaining
cases showed 60–90% consistency in different areas of the tumor,
suggesting significant tumor heterogeneity in both the fibroade-
noma and low-grade phyllodes tumor cases. The seven cases
included two fibroadenomas that were identified as low-grade
phyllodes tumor by the algorithm. After the mass spectra for all 31
cases of low-grade phyllodes tumor and 30 cases of fibroadenoma
are collected, an average peak value for all cases was generated.
There is no significant difference in any of the peaks identified,
and the overall mass spectra pattern is shown in Fig. 7.
DISCUSSION
Distinguishing a fibroadenoma from a low-grade phyllodes tumor
by pure morphology can be challenging, particularly on core
needle biopsies. Our study shows that, even when strictly
adhering to the diagnostic criteria, there is minimal difference in
the clinical characteristic and overall outcome between low-grade
phyllodes tumor and fibroadenoma and that perhaps separating
the two entities is neither possible nor desirable. Low-grade
phyllodes tumor are slightly larger in size and present in older
patients, but neither age or size differences are statistically
significant. We also demonstrated that low-grade phyllodes tumor
have a low risk for recurrence and malignant potential on long
term follow-up, which is similar to findings in other studies in the
literature12. Within the study cohort, the local recurrence rate of
low-grade phyllodes tumor was 6.5%, all of which were cured by
re-excision of the tumor bed. Whether this represented incom-
plete excision of the initial surgery, or rather a recurrence of the
tumor could not be further discerned in the retrospective data. We
did confirm that the margin status was all negative on evaluation
of initial resection. We also noted, however, that although there
were no reported “recurrences” for fibroadenomas, new lesions
were seen in the breast on mammography, and were often not
biopsied due to minimal risk of progression. There were no
malignant transformation or distal metastases in any of the low-
grade phyllodes tumor or fibroadenoma cases. In the three largest
studies to date, only 0.3% of low-grade phyllodes tumor
eventually developed metastatic disease13–15.
We reviewed the clinical outcome for high-grade phyllodes
tumor and 2 of the 8 (25.0%) patients with available follow-up
information died of metastatic disease 18 and 19 months after
surgery, respectively. This number is slightly above the 16.3% rate
reported in the literature13–15, likely due to the limited number of
patients with high-grade phyllodes tumor in our study. This
highlights the importance of distinguishing high-grade phyllodes
tumor from low-grade phyllodes tumor, which do show significant
prognostic differences.
There are no established criteria for evaluation of immunohis-
tochemistry stains to help classify or stratify fibroadenoma and
phyllodes tumor. In our study, Ki-67 showed lowest proliferative
index in fibroadenomas (median 2.0%, mean 2.5%, range 1 to
10%), followed by low-grade phyllodes tumor (median 6.0%, mean
7.7%, range 2 to 30%), with high-grade phyllodes tumor showing
the highest proliferation index (median 50.0%, mean 45.0%, range
20 to 70%). This is similar to results from previous studies, which
some also found high proliferation index to be associated with
worse clinical outcome16–18. The difference between fibroadeno-
mas and low-grade phyllodes tumor may be explained by a bias to
designate as phyllodes tumor those lesions with increased stromal
mitotic figures. Previous studies have shown p53 positivity to be
increased in phyllodes tumors16–18. We also observed the lowest
positivity in fibroadenomas (median 1.0%, mean 2.7%, range 1 to
20%), second low-grade phyllodes tumor (median 3.0%, mean
10.0%, range 1 to 60%), followed by high-grade phyllodes tumor
Fig. 3 Kaplan–Meier analysis does not show any significant difference in disease-free survival or overall survival in patients with
fibroadenoma and low-grade phyllodes tumor. Of note, the two cases of recurrent low-grade phyllodes tumor presented at the previous
resection sites, and no recurrences were reported after the re-excision.
L. Zhang et al.
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Fig. 4 Representative histologic and immunohistochemical images of fibroadenoma, low-grade phyllodes tumor, and high-grade
phyllodes tumor. Fibroadenoma (left column), low-grade phyllodes tumor (middle column), and high-grade phyllodes tumor (right column)
stained with hematoxylin and eosin (a–c, 100×), Ki-67 (d–f, 200×), p53 (g–i, 200×), and β-catenin (j–l, 200×).
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(median 20.0%, mean 30.5%, range 2 to 100%). β-catenin nuclear
staining has been used as a surrogate marker for Wnt signaling
pathway, which have been proposed to play a role in the
pathogenesis of phyllodes tumor19. β-catenin had highest nuclear
positivity in low-grade phyllodes tumor (median 60.0%, mean
48.8%, range 2 to 90%), followed by fibroadenoma (median 40.0%,
mean 38.2%, range 0 to 80%), with high-grade phyllodes tumor
rarely expressing the marker (median 0%, mean 9.5%, range 0 to
40%). The loss of nuclear β-catenin expression in high-grade
phyllodes tumor has been shown in previous studies and correlate
with worse prognosis20. Given the overlap in immunohistochem-
istry results for Ki-67, p53, and β-catenin, it would seem unlikely
that these markers would provide much additional information to
help distinguish fibroadenoma and phyllodes tumor. There was
one study showing E-cadherin in the stromal cells to correlate with
recurrence and shorter tumor-specific survival21, however, we did
Table 1. Mean percentage of tumor stromal cells positive for immunohistochemistry marker.
Fibroadenoma (A) Low-grade phyllodes tumor (B) High-grade phyllodes tumor (C) p-value A vs. B p-value A vs. C p-value B vs. C
Ki-67 2.5% 7.7% 45.0% <0.001 <0.001 <0.001
p53 2.7% 10.0% 30.5% <0.001 <0.001 0.01
β-catenin 38.2% 48.8% 9.5% 0.099 <0.001 <0.001
E-cadherin 0 0 0 1 1 1
Fig. 5 Box and whisker plot of immunohistochemistry results. Percentage of tumor stromal cells staining positive for immunohistochem-
istry markers Ki-67 (a), p53 (b), and β-catenin (c) in fibroadenoma (FA), low-grade phyllodes tumor (LGP), and high-grade phyllodes tumor
(HGP) is plotted. Center line represents median percentage of tumor stromal cells staining positive for each marker; the lower bound of box
represents first quartile; the upper bound of box represents third quartile; and whiskers extends to the lowest and highest staining
percentage of each marker. Note there is overlap in immunohistochemistry staining in the three entities. Wilcoxon-Mann–Whitney tests show
statistically significant difference (p < 0.05) in Ki-67 and p53 staining from FA to LGP to HGP. There is no difference in β-catenin staining
between FA and LGP, but there is statistically significant difference in nuclear staining for HGP compared with FA and LGP.
Fig. 6 Volcano plots for peak intensity comparison of the epithelial and stromal components of fibroadenoma and low-grade phyllodes
tumor, respectively, sampled by matrix-assisted laser desorption ionization (MALDI) imaging mass spectrometry (IMS). Each black point
on the plot is an individual m/z. The x-axis of the plot shows the fold change in peak intensity where data points on the left indicate higher
peak intensity in fibroadenoma and data points on the right indicate higher peak intensity in phyllodes tumor. The areas between the two
vertical black dotted lines indicated less than minimal change. The y-axis shows the p-value resulting from an unpaired t-test of fibroadenoma
vs. low-grade phyllodes tumor samples with the horizontal red dotted line indicating a significant threshold of 0.05 in p-value. The volcano
plot shows wider distribution of the data points in the stromal component (b) than in the epithelial component (a) indicating more difference
in the stromal component between the two entities. However, the data points are below the p < 0.05 threshold.
L. Zhang et al.
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not identify any staining for E-cadherin in the stromal component
of any of our cases. This difference may be attributed to the
alternative antibody clone used in our study.
Although immunohistochemistry studies have the advantage of
examining protein expression in the context of histomorphology,
the main caveat to this approach is that only selected proteins of
interest can be studied at a time. The choice of proteins that can
be studied is also restricted by the antibodies that are available.
Conventional mass-spectrometry can be utilized to study multiple
peptides, lipids, and other molecules, but lacks the capability of
spatial recognition. MALDI-IMS provides a platform with spatial
specificity to separately compare the stromal and epithelial
components between fibroadenoma and low-grade phyllodes
tumor. To our knowledge, our study is the first to look at the
proteomics constitution of the stromal and epithelial component
of low-grade phyllodes tumor and fibroadenoma separately.
Our results showed no significant difference in proteomic
profile of the stromal or the epithelial component between low-
grade phyllodes tumor and fibroadenoma, as the algorithm
generated from the mass spectra in the study set did not
confidently distinguish the two entities in the validation set.
Furthermore, the combined average of all the peaks generated for
the mass spectra showed no significant difference between the
two entities. Clinically, none of the low-grade phyllodes tumor or
the fibroadenoma cases in our study developed distant metastasis
on follow-up and by the fact that a total of five cases developed
subsequent lesions in the breast, two cases were low-grade
phyllodes tumor which were cured of disease on re-resection, and
the other three were cases of fibroadenoma and the new lesions
were not biopsied, likely a consequence of interpreting new
lesions preceded by a diagnosis of phyllodes tumor as a
recurrence and those by a diagnosis of fibroadenoma as multi-
centricity. It seems that a propensity for recurrence/multicentricity
cannot be accurately outlined by known histologic criteria nor by
the histology-directed mass spectral protein profiles. Given the
limited number of cases included in our study and the low
number of proteins analyzed, further investigation is warranted.
In the last two decades, the utility of next generation
sequencing has provided new insights in the classification and
pathogenesis of breast fibroepithelial lesions. The most important
and well-established finding has been the identification of hotspot
mutations in exon 2 of MED12, an X-linked gene encoding
mediator complex subunit 12, in fibroadenomas and phyllodes
tumors22–28, in the stromal components22,25,26. Mutational analysis
in several cohorts showed higher rate of MED12 exon 2 hotspot
mutations in fibroadenomas and lower grade phyllodes tumors,
particularly benign phyllodes tumors27,29–31, while genetic aberra-
tions in TP53, RB1, NF1, PIK3CA, ERBB4, and EGFR were more
commonly found in malignant phyllodes tumors23,31–33. Pareja
et al.34 reported a higher frequency of MED12 mutations in
phyllodes tumors with fibroadenoma-like areas, compared with
those without fibroadenoma-like areas, suggesting the progres-
sion of MED12-mutant fibroadenomas to a subset of phyllodes
tumors. Tan et al.31 used combined whole exome sequencing and
targeted deep sequencing of fibroepithelial lesions and revealed
similar genetic signatures between fibroadenomas and a subset of
benign phyllodes tumors. For diagnostic purposes, there have
been proposal of using an assay of five-gene transcript set (ABCA8,
Fig. 7 Mean spectra from the fibroadenoma and low-grade phyllodes tumor matrix-assisted laser desorption ionization (MALDI) imaging
mass spectrometry (IMS) data. Mean spectra were generated from normalized, recalibrated data. Result from epithelial component is shown
on top and the result from the stromal component is shown on the bottom. The x-axis of the plot is m/z whereas the y-axis is the mean
spectra. The bottom spectra (phyllodes tumor) in each plot are arbitrary flipped to make comparison easier. As shown, there is no visually
discernable difference in the mean spectra of fibroadenoma and low-grade phyllodes tumor.
L. Zhang et al.
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APOD, CCL19, FN1, and PRAME) for classifying breast fibroepithelial
lesions into fibroadenomas and phyllodes tumors35.
Most recent consensus12 acknowledged that the definitive
distinction between cellular fibroadenoma and benign phyllodes
tumor may not be crucial and indeed not necessary. We further
showed that conventional fibroadenoma and low-grade phyllodes
tumor (which also includes borderline phyllodes tumor) are
identical by proteomics analysis. Overall, the results from our
study as well as those of focusing on genetic aspects support the
interpretation these lesions are one and the same and a more
conservative surgical approach is justified by its indolent nature,
something that can be facilitated by avoiding the diagnosis of
phyllodes tumor, at least for those lesions designated as benign
phyllodes and those in which a distinction between fibroadenoma
and phyllodes tumor is difficult or not possible. In any case of
uncertainty, especially in core biopsies, rendering the diagnosis of
“benign fibroepithelial tumor” is preferable. Separating out the
high-grade (or malignant) phyllodes tumor, on the other hand, has
significant clinical implications. There are strict histologic criteria
and immunohistochemistry studies that add supporting evidence
to this distinction.
There were several limitations to our study that need to be
acknowledged. First, our study was retrospective in nature, and
was limited by the inherent bias associated with such approach.
Second, the number of cases in our study was relatively small. This
is mainly due to the fact that phyllodes tumor are much less
common in the area populated with Caucasians and African
Americans. Third, we did not include specific information on
laterality and location of the masses, which may provide
additional information in predicting availability for intervention
and/or tumor behavior. Lastly, we did not have enough cases of
phyllodes tumor with recurrence and/or metastasis to perform
MALDI-IMS, which would be of clinical relevance to differentiate
from other cases. Additional prospective studies with larger
cohorts, especially with large number of cases with recurrences




Our study was approved by the Washington University School of Medicine
Institutional Review Board, including a waiver of consent given the
retrospective nature of this study. The surgical pathology archives were
searched for partial or total mastectomies with a diagnosis, including the
word “phyllodes” from year 2006 to 2014. Archived histologic slides of
these cases and of a matching number of fibroadenomas were retrieved
and reviewed by three pathologists (C.Y., L.Z., and H.M.) blinded to the
clinical outcome information. All tumors were subclassified using both the
WHO2 and AFIP3 grading criteria. Fibroadenoma variants, including
juvenile fibroadenoma, cellular fibroadenoma, myxoid fibroadenoma,
and complex fibroadenoma with florid changes that obscure the under-
lying fibroadenomatous nature were excluded due to potential challenges
in accurate classification. Fibroadenomas with focal complex changes were
not excluded. A total of 31 cases with confirmed diagnosis of low-grade
phyllodes tumor and 30 consecutive cases of fibroadenoma were
identified and retrieved from archives. Clinical data for all cases of low-
grade phyllodes tumor and fibroadenoma were extracted from the
electronic medical records system for analysis. We additionally analyzed
all ten cases of high-grade phyllodes tumor identified with immunohis-
tochemistry using Ki-67, p53, β-catenin, and E-cadherin.
Immunohistochemistry
One representative formalin-fixed paraffin-embedded tissue block from
each case (31 low-grade phyllodes tumor, 30 fibroadenoma, and 10 high-
grade phyllodes tumor) was selected to generate 4 μm thick unstained
slides for immunohistochemical staining for the following antibodies: Ki-67
(clone 30-9, prediluted, Ventana), p53 (clone Bp53-11, prediluted, Ventana),
β-catenin (clone 14, prediluted, Ventana), and E-cadherin (clone EP700Y,
prediluted, Ventana). The immunohistochemistry staining was performed
on Ventana Benchmark automated immunostainer (Ventana Medical
Systems, Inc., Tucson, AZ) according to standard protocols with
Fig. 8 Procedure of matrix-assisted laser desorption ionization (MALDI) imaging mass spectrometry (IMS). Two serially sectioned 6 μm
sections from formalin-fixed paraffin-embedded tissue blocks are generated. One slide is stained with hematoxylin and eosin and scanned for
annotation. After the slide is annotated by the pathologists, the areas of interest are mapped on the unstained slide. After enzyme digestion
and matrix application, the mass spectra of individual annotated areas are obtained.
L. Zhang et al.
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appropriate positive and negative controls. The immunohistochemistry
staining results were interpreted individually by two pathologists (C.Y. and
L.Z.) blinded of the diagnosis. The percentage of cells positive was visually
estimated and recorded and the average of the two results were used for
analysis. Only nuclear staining for Ki-67, p53, and β-catenin in the stromal
tumor cells were considered as positive. In contrast, cytoplasmic and
membranous staining in the stromal tumor cells for E-cadherin was
interpreted as positive. The percentage of staining was estimated relative
to total number of stromal cells.
MALDI-IMS
Serial sections, 6 μm thick, were cut from the above selected blocks. One
section per sample was mounted onto indium tin oxide coated slide for
MALDI time-of-flight (TOF) analysis, whereas the consecutive section was
mounted onto a regular glass slide as a reference histologic section. The
slides were dried overnight at 37 °C and stored out of light until ready to
use. The reference slides were stained with H&E and scanned with an
automated slide scanner (Leica SCN 400, Leica Biosystems, Buffalo, Illinois)
at x20 magnification and uploaded to a web-based pathology interface for
mass-spectrometry (PIMS)36. Two pathologists (L.Z. and C.Y.) then
annotated the scanned images with color-coded circular marks (300 μm
in diameter). In each image of fibroadenoma or phyllodes tumor, 20 marks
(red circles) were assigned for the epithelial component and 20 marks
(purple circles) were assigned for the stromal components (preferably
adjacent to the epithelial lumina) (Fig. 8). In a subset of cases, surrounding
uninvolved breast stroma was annotated as reference (yellow circles).
Using image-processing software (Photoshop), the histology-annotated
image was merged with an image of the consecutive unstained section
and the coordinates of the annotations were determined. Serial sections
for MALDI TOF were deparaffinized and antigen retrieved. Briefly, slides
were deparaffinized in a series of xylenes, graded ethanol and water
washes and dried completely at room temperature. Antigen retrieval was
performed in a Coplin jar containing 10mM Tris buffer, pH 9, in a
decloaking chamber. The samples were brought to 95 °C in the decloaking
chamber for 20min, cooled to 90 °C for 10 s and removed from the
chamber. The slides were cooled in the Coplin jar for 20min prior to buffer
exchange with Milli-Q purified water. The slides were dried at room
temperature and stored over desiccant out of light. Trypsin and matrix
were applied to the discrete regions selected in PIMS using a Labcyte
Portrait 630 robotic spotter with a spotting error <60 µm37. Trypsin
(0.08 µg/µL solution) was deposited over a series of 40 iterations, 40
passes, one drop each pass (roughly 170 pL/drop) at each designated
coordinate to achieve a final concentration of ~29 ng/mm2. This was
completed over a total of 2 h to allow drying time between iterations.
Alpha-cyano-4-hydroxycinnamic acid matrix (5 mg/ml in 50% acetonitrile,
0.1% trifluoroacetic acid) was then applied over the digested spots over 72
iterations, 8 passes, 9 drops each pass. The samples were analyzed in
profiling mode on a Bruker UltrafleXtreme TOF MS in reflectron positive
mode. Data was sorted by patient and tissue type.
Acquired MALDI-IMS profiling data was processed using MALDIquant38
in the R environment. After data import, the spectra were baseline
corrected to remove MALDI chemical noise using the SNIP algorithm39
with 20 iterations. After baseline correction, the spectral data was
normalized by the total ion current to account for pixel-to-pixel signal
artifacts. Following normalization, the spectral data was statistically re-
aligned to a reference spectrum to remove inherent mass shifts from the
TOF instrument that can greatly affect classification quality. The reference
spectrum for realignment was closest spectrum to the 50th quantile of the
TIC distribution of all data. Following mass axis alignment, peaks with
signal-to-noise ratio above 3 were selected on the overall mean spectrum
from all data. The peak intensity data was integrated for each spectrum
resulting in a data matrix where observations (rows) are individual pixels
labeled by de-identified patient serial number and pathologist annotation
and variables (columns) are picked peak intensity data from the dataset
from each spectrum.
Machine learning on the picked peak MS data implemented the support
vector machine algorithm with a linear kernel. The model and cost
function (regularization) were tuned using 5-fold cross validation. The
tuned cost function was found to be 0.5 in this instance. Analysis of
significant different peaks between the two data classes was performed
using area under the receiver operator characteristic curve.
Statistics
Relationships between the variables were examined by Wilcoxon-
Mann–Whitney tests for comparison of means, Fisher-Exact tests for
comparison of categorical variables, and log-rank tests for comparison of
survival. All tests were two-sided.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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